IDR Data
CMS PUF data · 2023 Q1–2025 Q4

CPT 82746: Federal IDR outcomes

Folic acid level, serum

In 2025 Q1–Q4, the provider or facility offer prevailed in 86.2% of 160 determined Federal IDR dispute line items for CPT 82746. The median prevailing offer was 4.18x the QPA (25th–75th percentile 2.16x–8.49x; n = 108). The median time to a decision was 46 business days (n = 160).

Determined line items

160

2025 Q1–Q4 · 0 split decisions excluded

Provider win rate

86.2%

n = 160 · 2025 Q1–Q4

Median payment vs QPA

4.18x

middle half 2.16x–8.49x · n = 108 · 2025 Q1–Q4

Median days to decision

46

business days, from dispute initiation · n = 160 · 2025 Q1–Q4

Dollar amounts

Total awarded

$8,282

sum of prevailing offers · n = 38 · 2025 Q1–Q4

Total QPA

$2,372

sum of QPAs, same line items · n = 38 · 2025 Q1–Q4

Awarded above QPA

$5,910

total awarded minus total QPA · n = 38 · 2025 Q1–Q4

Median award per line item

$225

mean $218 · n = 38 · 2025 Q1–Q4

Median QPA

$45

per line item · n = 38 · 2025 Q1–Q4

Award vs QPA, dollar-weighted

3.49x

total awarded ÷ total QPA · n = 38 · 2025 Q1–Q4

Dollar amounts come from the separate CMS “QPA and Offers” file: line items decided for the provider or the plan with a non-suppressed QPA and prevailing offer. That file cannot be joined to the line items above, so its n differs. Awarded = the prevailing (selected) offer; it is not a record of what was paid. State comes from the file’s geographic region; a metro area that spans states counts in each. How the dollar figures work

Dollar amounts by period

PeriodLine items with $Total awardedTotal QPAAbove QPAMedian awardMedian QPAAward ×QPA ($-weighted)
2025 Q1–Q438$8,282$2,372$5,910$225$453.49x
2024 Q3–Q4Fewer than 30 line items with dollar amounts; not shown.
2024 Q3–2025 Q447$10,058$2,974$7,084$216$453.38x
2023 Q1–2024 Q2Not available (see methodology).

From the CMS QPA and Offers file (see above). Award ×QPA here is total awarded ÷ total QPA, so large claims weigh more than in the per-line median ratio.

By period

PeriodLine itemsWin %Median ×QPA25th–75thRatio nMedian days
2025 Q1–Q416086.2%4.18x2.16x–8.49x10846
2024 Q1–Q44080.0%––2674
2023 Q1–Q4Fewer than 30 determined line items; not shown.
2023 Q1–2025 Q420085.0%4.01x1.68x–8.49x134not pooled

Line items = determined dispute line items (n). Win rate excludes split decisions and includes default decisions. Ratio n = line items reporting a payment-to-QPA ratio. Days are business days as reported by CMS (2023–2024: from IDR entity assignment; 2025: from initiation) and are never pooled.

By state

State (place of service)Line itemsWin %Median ×QPARatio nMedian days
Tennessee4783.0%3.27x3641

2025 Q1–Q4 · rows with n ≥ 30 determined line items · sorted by n.

By specialty

Specialty groupLine itemsWin %Median ×QPARatio nMedian days
Hospitals and facilities12389.4%4.42x7952
Emergency medicine and emergency departments3275.0%–2543.5

2025 Q1–Q4 · rows with n ≥ 30 determined line items · sorted by n.

Section: Pathology and laboratory (80047–89398)

FAQ

What is the Federal IDR provider win rate for CPT 82746?

In 2025 Q1–Q4, the provider or facility offer was selected in 86.2% of 160 determined dispute line items for CPT 82746. Split decisions are excluded from the denominator and default decisions are included. Withdrawn, settled and ineligible disputes are not in the CMS data.

How do Federal IDR payments compare with the QPA for CPT 82746?

In 2025 Q1–Q4, the median prevailing offer was 4.18x the qualifying payment amount (QPA), with a 25th to 75th percentile range of 2.16x to 8.49x (n = 108 line items). This uses the CMS field Prevailing Party Offer as % of QPA, where 1.00x equals the QPA.

How long do Federal IDR decisions take for CPT 82746?

In 2025 Q1–Q4, the median was 46 business days (n = 160 line items), using the CMS field Length of Time to Make Determination (from dispute initiation).

How to Utilize IDR